Cyrus Therapeutics, Inc.

The hopes of spring may be returning to the South Korean biotech industry after a series of encouraging developments in recent months has more than made up for some other disappointing news, with prog

Targeted protein degradation (TPD) is becoming a popular choice for Korean pharma firms looking for new drug modalities and growth engines. They are making diverse moves, largely seeking R&D collabora

Investors have largely shied away from the South Korean biotech/pharma sector in the first quarter amid negative industry news including the possible delisting of oncolytic virus firm SillaJen, Inc.

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AzurRx Will Take First Wave Name After